Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
‘Unauthorized Alien’ Limits Among Trio of Auto Insurance Proposals Under Consideration in LA House Three auto insurance bills cleared the Louisiana House Committee on Civil Law and Procedure...
Social Media Bill Dodges Veto Override in CO Colorado Gov. Jared Polis’ (D) veto of a social media bill ( SB 86 ) survived an override attempt. The state’s Democrat-controlled Senate voted...
WA Enacts Law Keeping Medical Debt Off Credit Reports Washington Gov. Bob Ferguson (D) signed a bill ( SB 5480 ) prohibiting collection agencies from reporting unpaid medical debt to credit agencies...
In 2022, there were about 22 maternal deaths for every 100,000 live births in the United States. That’s the highest rate of maternal deaths among high-income nations worldwide. That sobering statistic...
DOGE-Like Effort in FL Could Impact Insurance Industry The wave of housecleaning that’s swept through the federal government courtesy of Elon Musk's Department of Government Efficiency appears...
California joined a nationwide movement to tighten restrictions on pharmacy benefit managers with the approval of SB 966 days before adjourning its legislative session on Aug. 31. If signed by Gov. Gavin Newsom (D) the measure will establish licensing requirements for PBMs and require them to report to the state’s Department of Insurance the fees they charge pharmacies and the rebates they receive from drug manufacturers. The bill would also require PBMs to pass along 100% of those rebates to health plans or insurers. (PLURIBUS NEWS, LEXISNEXIS STATE NET)
In 2021, Arkansas became the first state to pass a law requiring pharmaceutical manufacturers that participate in Medicaid to sell drugs to contract pharmacies at a discount under the federal 340B program. Louisiana followed suit in 2023. This year, Kansas (SB 28), Maryland (HB 1056), Mississippi (HB 728), Missouri (SB 751) and West Virginia (SB 325) enacted similar legislation. And other states, including New York (AB 7789), considered similar measures.
The recent legislative actions are pushback against the restriction of 340B drug sales by pharmaceutical companies, which contend the 340B program has expanded beyond its original intent. As of September 2023, 25 drugmakers had done so. (STATELINE)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.